UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

November 11, 2004

Commission File Number 0-21392

AMARIN CORPORATION PLC

(Translation of registrant's name into English)

7 Curzon Street
London W1J 5HG
England
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F o

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No ☒

The following exhibits are furnished as part of this Form 6-K:

Exhibit Number	Description
99.1	Press Release
99.2	Amarin Corporation plc interim financial statements as of and for the three months and nine months ended 30 September 2004 and 2003 (Unaudited)

This report on Form 6-K is hereby incorporated by reference in (a) the registration statement on Form F-3 (Registration No. 333-104748) of Amarin Corporation plc and in the prospectus contained therein, (b) the registration statement on Form F-3 (Registration No. 333-13200) of Amarin Corporation plc and in the prospectus contained therein and (c) the registration statement on Form F-3 (Registration No. 333-12642) of Amarin Corporation plc and in the prospectus contained therein, and this report on Form 6-K shall be deemed a part of each such registration statement from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished by Amarin Corporation plc under the Securities Act of 1933 or the Securities Exchange Act of 1934.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMARIN CORPORATION PLC

By: /s/ Richard A.B. Stewart.
Name: Richard A. B. Stewart
Title: Chief Executive Officer

Date: November 11, 2004

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release
99.2	Amarin Corporation plc interim financial statements as of and for the three months and nine months ended 30 September 2004 and 2003 (Unaudited)

Exhibit 99.1

Contact:
Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone +44 (0) 207 907 2442
investor.relations@amarincorp.com

Alan Cooke
Chief Financial Officer
Amarin Corporation plc

AMARIN CORPORATION REPORTS THIRD QUARTER 2004 FINANCIAL RESULTS

LONDON, United Kingdom, November 11, 2004 – Amarin Corporation plc (NASDAQSC: AMRN) today reported a net loss for the quarter ended September 30, 2004, including discontinued activities, of $1.2 million or $0.06 per American Depositary Share (ADS), compared with a net loss of $5.8 million or $0.32 per ADS in the quarter ended September 30, 2003.

Recent Highlights

- *Equity financing* – on October 7, a private placement of 13,474,945 ordinary shares raising gross proceeds for Amarin of $12.75 million was completed with a group of new and existing investors and management.

- *Significant investment by Amarin Chairman* – on October 6, Amarin's non-executive chairman, Mr. Thomas Lynch, acquired the entire debt and equity interest held in Amarin by Elan Corporation, plc ("Elan"), including 4,653,819 ADSs and a $5 million 5-year loan note.

- *Laxdale acquisition* – on October 8, Amarin completed the acquisition of Laxdale Limited ("Laxdale"), the company's research and development partner based in Stirling, Scotland .. The acquisition provides Amarin with a promising neuroscience pipeline in clinical development for central nervous system disorders. The most advanced candidate, Miraxion™, for which Amarin had originally licensed U.S. rights in November 2000, is in phase III for Huntington's disease and in phase II for treatment unresponsive depression.

- *Miraxion progress* – Miraxion, which has been granted fast track status for Huntington's disease by the FDA, is due to commence phase III trials in the first half of 2005. Amarin is in the process of finalizing the clinical trial protocol taking into consideration the valuable information obtained from discussions with the United States Food and Drug Administration ("FDA"), the European Medicines Evaluation Agency ("EMEA") and the additional analysis of the clinical data from the initial pivotal study. This analysis, in addition to observing a trend to statistical significance in the per protocol patient group, identified a sub-set of Huntington's disease patients (with a specific gene variant) that responded to Miraxion with statistical significance at 6 months and at 12 months. This sub-set of patients represents a significant majority of the Huntington's disease patient population.

- *Valeant dispute settlement* – on September 28, Amarin signed a settlement agreement with Valeant Pharmaceutical International, Inc ("Valeant") whereby $6 million of the $8 million in contingent milestones due to Amarin from Valeant were waived. The remaining $2 million due is now no longer contingent and is payable by Valeant to Amarin on November 30, 2004.

- *Total debt reduced to $2 million and maturity extended to 2009* – on October 7, Mr. Lynch agreed to convert $3 million of the $5 million loan notes into 2,717,391 ordinary shares with an option to convert the remaining $2 million at the offering price of any future equity financing. Thus, Amarin's total debt is reduced to $2 million with a maturity in 2009, if not previously converted.

- *Financial results* - operating loss from continuing activities for the third quarter of 2004 of $1.4 million, compared with an operating loss of $1.5 million in the third quarter of 2003.

Commenting on the results and progress made by Amarin in the third quarter, Rick Stewart, Amarin's Chief Executive Officer said, **"**the recent achievement of several significant milestones removes uncertainties for our investors and focuses activities on the preparation and commencement of phase III clinical studies in Huntington's disease. Amarin is in the process of finalizing the protocol and intends to commence patient recruitment in the first half of 2005."

The results for the third quarter and the nine months ended September 30, 2004 are analyzed between continuing and discontinued activities and are set out in further detail in the three pages of financial tables attached. Amarin's reported results for the third quarter and nine months ended September 30, 2004 do not include the results of Laxdale. The results of Laxdale will be consolidated with Amarin from the closing date of October 8, 2004.

Continuing Activities

The operating loss from continuing activities for the second quarter of 2004 was $1.4 million, compared with an operating loss of $1.5 million in the second quarter of 2003. For the nine months ended September 30, 2004, the operating loss from continuing activities was $4.6 million, compared with an operating loss of $5.3 million for the same period in 2003. This operating loss represents head office operating expenses, business and corporate development costs and Miraxion product rights amortization.

Discontinued Activities

For the quarter ended September 30, 2004, the profit before interest from discontinued activities was $0.3 million, compared with a loss before interest of $4.1 million for the same period in 2003.

The results for discontinued activities for the quarter ended September 30, 2004 reflect (i) the final costs incurred by Amarin relating to the completion of safety studies on Zelapar (the rights to which are owned by Valeant), (ii) the settlement of the outstanding dispute with Valeant, (iii) the final $1 million payment to Elan and (iv) the receipt of the final instalment of the proceeds of sale of Amarin's Swedish drug delivery business to Watson in October 2003.

Following the sale of the majority of Amarin's U.S. operations to Valeant in the first quarter of 2004, Amarin remained responsible for the cost of undertaking safety studies on Zelapar and was liable for up to $2.5 million of development costs. That obligation has now been fulfilled and Amarin will not incur any more costs relating to the development of Zelapar.

As previously announced, Amarin settled its outstanding dispute with Valeant in September. Under the main terms of the settlement agreement Amarin agreed to waive $6 million of the $8 million in contingent milestones due to Amarin from Valeant. The remaining $2 million is now no longer contingent and is payable by Valeant to Amarin on November 30, 2004. As a result, the $2 million fixed payment is included as other income in Amarin's income statement for the third quarter. Also, Valeant eliminated Amarin's $414,000 contingent obligation to re-purchase further inventory from wholesalers.

On receipt of the $2 million from Valeant on November 30, Amarin will pay $1 million to Elan as part of the settlement agreement entered into with Elan in February 2004. This $1 million payment to Elan is included in Amarin's income statement for the third quarter as an exceptional loss. After this final $1 million payment to Elan, Amarin will have no other outstanding liabilities or obligations to Elan.

Finally, the receipt of $0.4 million, representing the final instalment of the proceeds of sale of Amarin's Swedish drug delivery business to Watson in October 2003, is included as an exceptional gain.

For the nine months ended September 30, 2004, Amarin earned a profit before interest of $21.7 million on discontinued activities (compared with a loss of $10.4 million for the same period in 2003) which includes an exceptional loss of $2.4 million on disposal of the majority of its U.S. operations and certain products and an exceptional gain of $24.6 million on the settlement of debt obligations to Elan. A non-cash deferred tax accounting charge of $7.5 million arose on this exceptional gain which offsets a deferred tax asset of an equivalent amount included in the balance sheet as at December 31, 2003.

The results for discontinued activities for the comparative quarter and the nine month period ended September 30, 2003 reflect the results of Amarin's US business and the results of Amarin's Swedish drug delivery business that were sold in February 2004 and October 2003 respectively.

Balance Sheet

At September 30, 2004 Amarin had cash of $2.8 million. Subsequent to the quarter end, on October 7, 2004, Amarin raised gross proceeds of $12.75 million through the completion of a private placement of 13,474,945 ordinary shares. This provides Amarin with sufficient cash to fund the group's operating activities, including the planned phase III trials for Miraxion in Huntington's disease, through the summer of 2005.

Amarin's financing strategy will depend on the timing of clinical trial expenditure on its development pipeline and on the level of revenue generated from its licensing and partnering activities. As previously described, Amarin is seeking to partner the rights to its development pipeline for all indications (including depression) outside neurology and for geographic markets outside the United States. Amarin plans to directly commercialize its pipeline in the U.S. neurology market.

At September 30, 2004, Amarin had a $5 million 5-year loan note owing to Elan. On September 29, Amarin's non-executive chairman, Mr. Thomas Lynch, signed an agreement to acquire Elan's entire debt and equity interest in Amarin, including the $5 million loan notes. Mr. Lynch subsequently agreed to convert $3 million of the $5 million loan notes into 2,717,391 ordinary shares with an option to convert the remaining $2 million at the offering price of any future equity financing. This leaves Amarin with total debt of $2 million with a maturity in 2009, if not previously converted, and a significantly reduced annual cash interest expense of US$0.16 million reduced from US$0.4 million.

With respect to Amarin's stock market listing, Amarin must maintain sustainable shareholders equity in excess of $2.5 million or the value of the Company's listed securities must exceed $35 million. The completion of the settlement agreement with Valeant, the $12.75 million equity financing and the conversion of $3 million of debt to equity, collectively increased Amarin's shareholder's equity by approximately $16 million. This, together with the increase in Amarin's share price, defers any risk of Amarin's ADS's being delisted from the Nasdaq Small Cap market.

Amarin currently has 37,632,123 ordinary shares in issuance. This includes the private placement of 13,474,945 ordinary shares, the conversion of $3 million of the outstanding loan notes into 2,717,391 ordinary shares and the issuance of 3,500,000 ordinary shares on the acquisition of Laxdale.

Rick Stewart continued, "The integration of Laxdale is proceeding well. As a priority, significant resources are being applied to the upcoming Huntington's disease clinical trials. Additionally, evaluation of the treatment unresponsive data is ongoing. Our expectation is that a partner for this compound will be signed later in 2005. The Laxdale acquisition was closed a month ago and so far our expectations about the quality of the pipeline and science have been exceeded."

About Amarin Corporation
Amarin Corporation plc is a neuroscience company focused on the development and commercialisation of novel drugs for the treatment of central nervous system disorders. Miraxion, Amarin's lead development compound, is in phase III development for Huntington's disease and in phase II development for treatment unresponsive depression.

For press releases and other corporate information, visit our website at http://www.amarincorp.com.

Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties which may cause the Company's actual results in future periods to be materially different from any performance suggested herein. Such risks and uncertainties include, without limitation, the uncertainty of entering into and consummating a definitive agreement on terms acceptable to the parties, the inherent uncertainty of pharmaceutical research, product development and commercialisation, the impact of competitive products and patents, as well as other risks and uncertainties detailed from time to time in periodic reports. For more information, please refer to Amarin Corporation's Annual Report for 2003 on Form 20-F and its Form 6-Ks as filed with the U.S. Securities and Exchange Commission. The company assumes no obligation to update information on its expectations.

Exhibit 99.2

Amarin Corporation plc
Period Ended 30 September 2004 Selected Data (UK GAAP - UNAUDITED)

Selected Income Statement Data - extract of continuing activities

	Three months ended 30 September		Nine months ended 30 September	
	2004 Total $'000	2003 Total $'000	2004 Total $'000	2003 Total $'000
Revenue:				
Total revenue from continuing activities	—	—	—	—
	—	—	—	—
Operating expenses:				
Selling, General & Administrative	1,207	1,312	4,169	4,845
Amortisation of intangible assets	144	182	432	432
Operating expenses from continuing activities	1,351	1,494	4,601	5,277
Operating (loss) from continuing activities	**(1,351)**	**(1,494)**	**(4,601)**	**(5,277)**

Selected Income Statement Data - extract of discontinued activities

	Three months ended 30 September		Nine months ended 30 September	
	2004 Total $'000	2003 Total $'000	2004 Total $'000	2003 Total $'000
Revenue:				
Total revenues from discontinued activities	**—**	**4,557**	**1,017**	**10,419**
Cost of sales:				
Cost of sales from discontinued activities	**—**	**1,341**	**107**	**7,811**
Gross profit				
Total gross profit from discontinued activities	**—**	**3,216**	**910**	**2,608**
Operating expenses/(income):				
Selling, General & Administrative	—	4,310	1,575	11,972
Amortisation of intangible assets	—	1,222	—	3,668
(Gain) on renegotiation of Elan debt	—	—	—	(7,500)
Selling, General & Administrative from discontinued activities	—	5,532	1,575	8,140
Research & development from discontinued activities	1,117	1,748	2,500	4,868
Other (income) - Valeant settlement	(2,000)	—	(2,000)	—
Total operating (income)/expenses	**(883)**	**7,280**	**2,075**	**13,008**
Operating profit/(loss) from discontinued activities	883	(4,064)	(1,165)	(10,400)
Exceptional income/(expense) - discountinued activities				
Escrow proceeds of Q4 2003 Swedish disposal	400	—	750	—
Loss on disposal of US operations and certain products	(9)	—	(2,447)	—
(Loss)/gain on settlement of debt on related sale of distribution rights	(1,000)	—	24,572	—
Profit/(loss) on ordinary activities before interest - discontinued activities	**274**	**(4,064)**	**21,710**	**(10,400)**

	Three months ended 30 September		Nine months ended 30 September	
	2004 Total $'000	2003 Total $'000	2004 Total $'000	2003 Total $'000
Revenue:				
Total revenue from continuing activities	—	—	—	—
Revenues from discontinued activities	—	4,557	1,017	10,419
Total revenues	**—**	**4,557**	**1,017**	**10,419**
Cost of sales:				
Direct costs	—	1,341	107	7,811
Cost of sales from discontinued activities	**—**	**1,341**	**107**	**7,811**
Gross profit				

Continuing activities	—	—	—	—
Discontinued activities	—	3,216	910	2,608
Total gross profit	**—**	**3,216**	**910**	**2,608**
Operating expenses/(income):				
Selling, General & Administrative	1,207	1,312	4,169	4,845
Amortisation of intangible assets	144	182	432	432
Operating expenses from continuing activities	1,351	1,494	4,601	5,277
Selling, General & Administrative	—	4,310	1,575	11,972
Amortisation of intangible assets	—	1,222	—	3,668
(Gain) on renegotiation of Elan debt	—	—	—	(7,500)
Selling, General & Administrative from discontinued activities	—	5,532	1,575	8,140
Research & development from discontinued activities	1,117	1,748	2,500	4,868
Other income - Valeant settlement	(2,000)	—	(2,000)	—
Operating (income)/expenses from discontinued activities	(883)	7,280	2,075	13,008
Total selling, general & administrative	1,351	7,026	6,176	13,417
Total research & development	1,117	1,748	2,500	4,868
Other income - Valeant settlement	(2,000)	—	(2,000)	—
Total operating expenses	**468**	**8,774**	**6,676**	**18,285**
Operating (loss) from continuing activities	(1,351)	(1,494)	(4,601)	(5,277)
Operating profit/(loss) from discontinued activities	883	(4,064)	(1,165)	(10,400)
				—
Total operating (loss)	**(468)**	**(5,558)**	**(5,766)**	**(15,677)**
Exceptional income/(expense) - discountinued activities				
Escrow proceeds of Q4 2003 Swedish disposal	400	—	750	—
(Loss) on disposal of US operations and certain products	(9)	—	(2,447)	—
(Loss)/gain on settlement of debt on related sale of distribution rights	(1,000)	—	24,572	—
(Loss)/profit on ordinary activities before interest				
Continuing activities	(1,351)	(1,494)	(4,601)	(5,277)
Discontinued activities	274	(4,064)	21,710	(10,400)
	(1,077)	**(5,558)**	**17,109**	**(15,677)**
Net interest payable	(89)	(196)	(186)	(643)
(Loss)/income before taxes	**(1,166)**	**(5,754)**	**16,923**	**(16,320)**
				—
Income tax (expense)	—	(3)	(7,500)	(146)
Dividends payable	—	—	—	(24)
Net (loss)/income for the period	**(1,166)**	**(5,757)**	**9,423**	**(16,490)**
				—
Weighted average shares - basic	17,940	17,932	17,940	16,810
Weighted average shares - diluted	17,940	17,944	17,940	16,822
			—	—
(Loss)/income per share:	$	$	$	$
Basic	(0.06)	(0.32)	0.53	(0.98)
Diluted	(0.06)	(0.32)	0.53	(0.98)

1. Select Balance Sheet Data

	As at 30 September	
	2004	2003
	$'000	$'000
Net current assets/(liabilities)	4,228	(48,352)
Cash	2,813	3,931
Debtors (see note 4)	5,433	3,440
Total assets	12,098	56,987
Long term creditors and provisions (see note 5)	(5,000)	(410)
Called up share capital (ordinary shares) and capital redemption reserve	29,088	29,076
Total shareholders' funds/(deficit)	3,080	(3,226)

2. EBITDA

	Three months ended 30 September	
	2004	2003
	$'000	$'000
(Loss) for period	(1,166)	(5,757)

amortisation	144	1,404
interest	89	196
taxation	—	3
foreign exchange	—	0
EBITDA	**(933)**	**(4,154)**

3. The selected financial data set out above should be read in-conjunction with our 2003 20-F Annual Report which is filed with the SEC.

4. As previously described, Amarin provided Laxdale with a loan facilty, secured by a floating charge against Laxdale's assets. At September 30, 2004, the total loan owed by Laxdale to Amarin amounted to $1.8 million and is included in net current assets. The accounting for the acquisition of Laxdale will have the effect of increasing the goodwill that arises on acquisition by the amount of this loan.

5. At September 30, 2004, Amarin had a $5 million 5-year loan note owing to Elan. On September 29, Amarin's non-executive chairman, Mr. Thomas Lynch, signed an agreement to acquire Elan's entire debt and equity interest in Amarin, including the $5 million loan notes. Mr. Lynch subsequently agreed to convert $3 million of the $5 million loan notes into ordinary shares with an option to convert the remaining $2 million at the offering price of any future equity financing. The remaining $2 million loan notes have a maturity date of January 2009. The annual interest coupon payable by Amarin on the remaining $2 million loan notes is 8% or $0.16 million.

6. Shareholders' Equity/(Deficit)

	30-Sep-04 $'m
UK GAAP	**3.1**
Lax-101 product rights	(3.6)
Income recognition	(0.6)
Unamortised discount on loan	0.4
Preference dividends	0.5
US GAAP	**(0.2)**

7. Basis of preparation

At September 30, 2004 Amarin had cash of $2.8 million. On October 7, 2004, Amarin raised gross proceeds of $12.75 million through the completion of a private placement of ordinary shares. This provides Amarin with sufficient cash to fund the group's operating activities, including the planned phase III trials for Miraxion in Huntington's disease, through the summer of 2005. Amarin's future financing strategy will depend on the timing of clinical trial expenditure on its development pipeline and on the level of revenue generated from its licensing and partnering activities.

Amarin intends to fund its operations and research and development activities beyond the summer of 2005 by obtaining additional funding through earning revenue from its licensing and partnering activties and/or completing further equity-based financings. There is no assurance that Amarin's efforts to raise additional funding will be successful. If efforts are unsuccessful, there is uncertainty as to whether Amarin will be able to fund its business beyond the summer of 2005. These financial statements do not include any adjustments that might be necessary should such funding not be available.

Amarin believes it will be successful in obtaining further funds as described above and thus, have prepared the accounts for the third quarter on a going concern basis.